Radiotherapy in conjunction with intravenous infusion of 180 mg of disodium pamidronate in management of osteolytic metastases from breast cancer: Clinical evaluation, biochemical markers, quality of life, and monitoring of recalcification using assessments of gray-level histogram in plain radiographs

International Journal of Radiation Oncology Biology Physics

Volumn 57, Issue 1, 2003, Pages 143-157

  Kouloulias, Vassilis ^a,b   Matsopoulos, George ^b   Kouvaris, John ^a   Dardoufas, Costas ^a   Bottomley, Andrew ^c   Varela, Maria ^d   Uzunoglu, Nikos ^b   Antypas, Christos ^a   Metafa, Anna ^a   Moulopoulos, Antzela ^a   Sandilos, Panagiotis ^a   Vlahos, Lambros ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b NATIONAL TECHNICAL UNIVERSITY OF ATHENS   (Greece)

^c EORTC DATA CENTER   (Belgium)

^d IASO GENERAL HOSPITAL   (Greece)

Author keywords

Disodium pamidronate; EORTC QLQ C30 quality of life questionnaire; Image processing techniques; Osteolytic metastases; Prognostic factors; Radiotherapy

Indexed keywords

BIOCHEMISTRY; DISEASES; IMAGE PROCESSING; RADIOGRAPHY; RADIOTHERAPY;

BREAST CANCERS;

ONCOLOGY;

ALKALINE PHOSPHATASE BONE ISOENZYME; CALCIUM; CREATININE; HYDROXYPROLINE; PAMIDRONIC ACID; PARACETAMOL;

ARTHRALGIA; ARTICLE; ASTHENIA; BONE METASTASIS; BONE PAIN; BONE RADIOGRAPHY; BREAST CANCER; CALCIUM URINE LEVEL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE URINE LEVEL; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HEART ARRHYTHMIA; HEART PALPITATION; HISTOGRAM; HUMAN; HYDROXYPROLINE URINE LEVEL; HYPERCALCEMIA; HYPOCALCEMIA; HYPOPHOSPHATEMIA; LINEAR ACCELERATOR; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; MYALGIA; OSTEOLYSIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RADIATION DOSE; RANK SUM TEST; SIDE EFFECT; STATISTICAL SIGNIFICANCE;

EID: 10744231831     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(03)00525-X     Document Type: Article

References (69)

1. Galasko C.S.B. Mechanisms of bone destruction in the development of skeletal metastases. Nature. 263:1976;507-508.
2. Coleman R.E., Rumens R.D. The clinical course of bone metastases from breast cancer. Br J Cancer. 55:1987;61-66.
3. Schocker J.D., Brady L.W. Radiation therapy for bone metastasis. Clin Orthop. 169:1982;38-43.
4. Jardines L., Callans L.S., Torosian M.H. Recurrent breast cancer Presentation, diagnosis, and treatment . Semin Oncol. 20:1993;538-547.
5. Hoskin P.J. Scientific and clinical aspects of radiotherapy in the relief of bone pain. Cancer Surv. 7:1988;69-86.
6. Kagan A.R., Bassett L.W., Steckel R.J., et al. Radiologic contributions to cancer management Bone metastases . AJR Am J Roentgenol. 147:1986;305-312.
7. Flanagan A.M., Chambers T.J. Inhibition of bone resorption by bisphosphonates Interactions between bisphosphonates, osteoclasts, and bone . Calcif Tissue Int. 49:1991;407-415.
8. Jung A., Bizas S., Fleisch H. The binding of pyrophosphate and two diphosphonates on hydroxyapatite crystals. Calcif Tissue Res. 11:1973;269-280.
9. Morton A.R., Cantrill J.A., Pillai G.V., et al. Sclerosis of lytic bone metastases after disodium aminohydroxpropylidene bisphosphonate (APD) in patients with breast cancer. BMJ. 297:1988;772-773.
10. Taylor A.K., Lundy M.W., Libant C.R., et al. Diagnostic test for metabolic bone and mineral disorders. Manolagas S.C., Olefsky J.M. Metabolic bone and mineral disorders. 1988;33-62 Churchill-Livingstone, New York.
11. Hillner B.E., Ingle J.N., Berenson J.R., et al. for the American Society of Clinical Oncology Bisphosphonates Expert Panel American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer . J Clin Oncol. 18:2000;1378-1391.
12. Hortobagyi G., Theriault R., Lipton A., et al. Long term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol. 16:1998;2038-2044.
13. Body J.J. Bone metastases and tumor-induced hypercalcemia. Curr Opin Oncol. 4:1992;624-631.
14. Coleman R.E., Purohit O.P., Vinholes J.J., et al. High dose pamidronate Clinical and biochemical effects in metastatic bone disease . Cancer. 80:(Suppl. 8):1997;1686-1690.
15. Fitton A., McTavish D. Pamidronate A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease . Drugs. 41:1991;289-318.
16. Garnero P., Darte C., Delmas P.D. A model to monitor the efficacy of alendronate treatment in women with osteoporosis using a biochemical marker of bone turnover. Bone. 24:1999;603-609.
17. Greenspan S.L., Parker R.A., Ferguson L., et al. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women A randomized clinical trial . J Bone Miner Res. 13:1998;1431-1438.
18. Pedrazzoni M., Alfano F.S., Gatti C., et al. Acute effects of bisphosphonates on new and traditional markers of bone resorption. Calcif Tissue Int. 57:1995;25-29.
19. Rosen H.N., Moses A.C., Garber J., et al. Utility of biochemical markers of bone turnover in the follow-up of patients treated with bisphosphonates. Calcif Tissue Int. 63:1998;363-368.
20. Ross P.D., Knowlton W. Rapid bone loss is associated with increased levels of biochemical markers. J Bone Miner Res. 13:1998;297-302.
21. Schlosser K., Scigalla P. Biochemical markers as surrogates in clinical trials in patients with metastatic bone disease and osteoporosis. Scand J Clin Lab Invest. 227:1997;21-28.
22. Hildebolt C.F., Brunsden B., Yokoyama-Crothers N., et al. Comparison of reliability of manual and computer-intensive methods for radiodensity measures of alveolar bone loss. Dentomaxillofac Radiol. 27:1998;245-250.
23. Kouloulias V., Antypas C., Dardoufas C., et al. Evaluation of recalcification of bone metastases after radiotherapy and I.V. infusion of disodium pamidronate, using image processing techniques: Comparative assessment using measurements of the optical density of plain radiography. Phys Med. 17:2001;17-24.
24. Southard T.E., Southard K.A. Detection of simulated osteoporosis in maxillae using radiographic texture analysis. IEEE Trans Biom Eng. 43:1996;123-132.
25. Purohit O.P., Anthony C., Radsone C.R., et al. High dose intravenous pamidronate for metastatic bone pain. Br J Cancer. 70:1994;554-558.
26. Green S., Weiss G.R. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs. 10:1992;239-253.
27. Theriault R.L., Lipton A., Hortobagyi G.N., et al. for the Protocol 18 Aredia Breast Cancer Study Group Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial . J Clin Oncol. 17:1999;846-854.
28. Aaronson N.K., Ahmedzai S., Bergman B., et al. The European Organization for Research and Treatment of Cancer QLQ-C30 A quality-of-life instrument for use in international clinical trials in oncology . J Natl Cancer Inst. 85:1993;365-376.
29. Hoggarth C.R., Bennett R., Daley-Yates P.T. The pharmacokinetics and distribution of pamidronate for a range of doses in the mouse. Calcif Tissue Int. 49:1991;416-420.
30. Pass B., Furkart A.J., Dove S.B., et al. 6-bit and 8-bit digital radiography for detecting simulated periodontal. Oral Surg Oral Med Oral Pathol. 77:1994;406-411.
31. Chen S.K., Hollender L. Digitising of radiographs with a flatbed scanner. J Dent. 23:1995;205-208.
32. Pratt W.K. Digital image processing. 1991;243-559 Wiley, New York. 563, 584-587.
33. Kouloulias V., Dardoufas C., Kouvaris J., et al. New approach in the evaluation of the use of disodium pamidronate in conjunction with radiotherapy in the management of bone metastases using image processing techniques. Acta Oncol. 41:2002;169-174.
34. Siegel S., Castellan J. Jr. Nonparametric statistics for the behavioral sciences. 2nd ed:1988;McGraw Hill, New York.
35. Cox D.R. Regression models and life tables. J R Stat Soc. 34:1972;187-220.
36. Webber R.L., Underhill T.E., Horton R.A., et al. Predicting osseous changes in ankle fractures. IEEE Eng Med Biol. 1993;103-109.
37. Wachenfeld I., Sanner G., Bottcher H.D., et al. The remineralization of the vertebral metastases of breast carcinoma after radiotherapy. Strahlenther Onkol. 172:1996;332-341.
38. Koswig S., Budach V. Remineralization and pain relief in bone metastases after different radiotherapy fractions (10 times 3 Gy vs. 1 time 8 Gy): A prospective study. Strahlenther Onkol. 175:1999;500-508.
39. Shapiro C.L., Keating J., Angell J.E., et al. Monitoring therapeutic response in skeletal metastases using dual-energy X-ray absorptiometry A prospective feasibility study in breast cancer patients . Cancer Invest. 17:1999;566-574.
40. Revilla M., Arribas I., Sanchez-Chapado M., et al. Total and regional bone mass and biochemical markers of bone remodeling in metastatic prostate cancer. Prostate. 35:1998;243-247.
41. Rizzoli R., Forni M., Schaad M.A., et al. Effects of oral clodronate on bone mineral density in patients with relapsing breast cancer. Bone. 6:1996;531-537.
42. Alhava E.M. Bone density measurements. Calcif Tissues Int. 49:(Suppl. 1):1991;S21-S23.
43. Avioli L.B., Lindsay R. The female osteoporotic syndrome(s). Avioli L.V., Krane S.M. Metabolic bone disease and clinically related disorders. 1990;397-451 WB Saunders, Philadelphia.
44. Whitlock J.P., Evans A.J., Jackson L., et al. Imaging of metastatic breast cancer Distribution and radiological assessment at presentation . Clin Oncol (R Coll Radiol). 13:2001;181-186.
45. Crilly R.G., Sebaldt R.J., Hodsman A.B., et al. Predicting subsequent bone density response to intermittent cyclical therapy with etidronate from initial density response in patients with osteoporosis. Osteoporos Int. 11:2000;607-614.
46. Oni O.O., Graebe A., Pearse M., et al. Prediction of the healing potential of closed adult tibial shaft fractures by bone scintigraphy. Clin Orthop. 245:1989;239-245.
47. Fleisch H. Bisphosphonates in bone disease. From the laboratory to the patient. 2000;129-130 Academic Press, San Diego.
48. Ravin P., Clemmesen B., Christiansen C. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Bone. 24:1999;237-244.
49. de Wit S., Cleton F.J. Hypercalcemia in patients with breast cancer A survival study . J Cancer Res Clin Oncol. 120:1994;610-614.
50. Francini G., Montagnani M., Petrioli R., et al. Comparison between CEA, TPA, CA 15/3 and hydroxyproline, alkaline phosphatase, whole body retention of 99mTc MDP in the follow-up of bone metastases in breast cancer. Int J Biol Markers. 5:1990;65-72.
51. Fontana A., Delmas P.D. Markers of bone turnover in bone metastases. Cancer. 88:(Suppl. 12):2000;2952-2960.
52. Coleman R.E., Smith P., Rubens R.D. Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer. 77:1998;336-340.
53. Colleoni M., O'Neill A., Goldhirsch A., et al. Identifying breast cancer patients at high risk for bone metastases. J Clin Oncol. 18:2000;3925-3935.
54. Saarto T., Blomqvist C., Virkkunen P., et al. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients 5-year results of a randomized controlled trial . J Clin Oncol. 19:2001;10-17.
55. Osoba D., Rodrigues G., Myles J., et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 16:1998;139-144.
56. Rose C.M., Kagan A.R. The final report of the expert panel for the Radiation Oncology Bone Metastasis Work Group of the American College of Radiology. Int J Radiat Oncol Biol Phys. 40:1998;1117-1124.
57. Body J.J. Bisphosphonates. Eur J Cancer. 34:1998;263-269.
58. Kouloulias V.E., Dardoufas C., Kouvaris J., et al. A comment from a radiotherapeutic point of view regarding the ASCO guidelines on the role of bisphosphonates in breast cancer. J Clin Oncol. 19:2001;2106.
59. Trombetti A., Arlot M., Thevenon J., et al. Effect of multiple intravenous pamidronate courses in Paget's disease of bone. Rev Rheum Engl Ed. 66:1999;467-476.
60. Adamson B.B., Gallacher S.J., Byars J., et al. Mineralisation defects with pamidronate therapy for Paget's disease. Lancet. 342:1993;1459-1460.
61. Bertolini D.R., Nedwin G.E., Bringman T.S., et al. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumor necrosis factors. Nature. 319:1986;516-518.
62. Wall J., Ratcliffe W.A., Howell A., et al. Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases The role of parathyroid hormone-related protein . Br J Cancer. 70:1994;169-172.
63. Ali S.M., Esteva F.J., Hortobagyi G., et al. Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J Clin Oncol. 19:2001;3434-3437.
64. Markowitz G.S., Appel G.B., Fine P.L., et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol. 12:2001;1164-1172.
65. Machado C.E., Flombaum C.D. Safety of pamidronate in patients with renal failure and hypercalcemia. Clin Nephrol. 45:1996;175-179.
66. Purohit O.P., Radstone C.R., Anthony C., et al. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. Br J Cancer. 72:1995;1289-1293.
67. Vinholes J.J., Guo C.Y., Purohit O.P., et al. Evaluation of new bone resorption markers in a randomised comparison of pamidronate or clodronate for hypercalcaemia of malignancy. J Clin Oncol. 15:1996;131-138.
68. Plunkett T.A., Smith P., Rubens R.D. Risk of complications from bone metastases in breast cancer Implications for management . Eur J Cancer. 36:2000;476-482.
69. Lipton A., Demers L., Curley E., et al. Markers of bone resorption in patients treated with pamidronate. Eur J Cancer. 34:1998;2021-2026.